The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Open accessAbstract
Significant progress has been made in recent years towards realizing the potential of natural killer (NK) cells for cancer immunotherapy. NK cells can respond rapidly to transformed and stressed cells, and have the intrinsic potential to extravasate and reach their targets in almost all body tissues. In addition to donor-derived primary NK cells, also the established NK cell line NK-92 is being developed for adoptive immunotherapy, and general safety of infusion of irradiated NK-92 cells has been established in phase I clinical trials with clinical responses observed in some of the cancer patients treated. To enhance their therapeutic utility, NK-92 cells have been modified to express chimeric antigen receptors (CARs) composed of a tumor-specific scFv antibody fragment fused via hinge and transmembrane regions to intracellular signaling moieties such as CD3ζ, or composite signaling domains containing a costimulatory protein together with CD3ζ. CAR-mediated activation of NK cells then bypasses inhibitory signals and overcomes NK resistance of tumor cells. In contrast to primary NK cells, CAR-engineered NK-92 cell lines suitable for clinical development can be established from molecularly and functionally well characterized single cell clones following good manufacturing practice (GMP)-compliant procedures. In preclinical in vitro and in vivo models, potent antitumor activity of NK-92 variants targeted to differentiation antigens expressed by hematologic malignancies, and overexpressed or mutated self-antigens associated with solid tumors has been found, encouraging further development of CAR-engineered NK-92 cells. Importantly, in syngeneic mouse tumor models induction of endogenous antitumor immunity after treatment with CAR-expressing NK-92 cells has been demonstrated, resulting in cures and long-lasting immunological memory protecting against tumor rechallenge at distant sites. Here we summarize the current status and future prospects of CAR-engineered NK-92 cells as off-the-shelf cellular therapeutics, with special emphasis on ErbB2 (HER2)-specific NK-92 cells that are approaching clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martín-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,353
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,060
Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells
Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., & Trinchieri, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20010938 · Cited by 1,028
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Self-citationFerlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M., & Münz, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011149 · Cited by 994
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Gong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 723
Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells
Piccioli, D., Sbrana, S., Melandri, E., & Valiante, N. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20010934 · Cited by 701
NK cell development, homeostasis and function: parallels with CD8+ T cells
Sun, J. C., & Lanier, L. L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3044 · Cited by 700
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Self-citationImai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Natural-killer cells and dendritic cells: “l'union fait la force”
Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L., & Vivier, E. (2005) · Blood · doi:10.1182/blood-2005-03-1154 · Cited by 634
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Self-citationTanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Self-citationChu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0985 · Cited by 435
Waldmann, T. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 434
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Vitale, M., Chiesa, M. D., Carlomagno, S., Pende, D., Aricò, M., Moretta, L., & Moretta, A. (2005) · Blood · doi:10.1182/blood-2004-10-4035 · Cited by 414
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Klingemann, H., Boissel, L., & Toneguzzo, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00091 · Cited by 414
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., Zhang, B., Lenvik, A. J., Panoskaltsis-Mortari, A., Verneris, M. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2710 · Cited by 391
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Self-citationCarrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., Ratto, G. B., Mingari, M. C., Moretta, L., & Ferlazzo, G. (2008) · Cancer · doi:10.1002/cncr.23239 · Cited by 379
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Self-citationHan, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1761-x · Cited by 328
Self-citationGoing viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
Koch, J., Steinle, A., Watzl, C., & Mandelboim, O. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.01.003 · Cited by 317
Halama, N., Braun, M., Kahlert, C., Spille, A., Quack, C., Rahbari, N., Koch, M., Weitz, J., Kloor, M., Zoernig, I., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2173 · Cited by 300
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92
Tonn, T., Becker, S., Esser, R., Schwabe, D., & Seifried, E. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/15258160152509145 · Cited by 267
Self-citationJiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Self-citationFactors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92
Maki, G., Klingemann, H.-G., Martinson, J. A., & Tam, Y. K. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/152581601750288975 · Cited by 262
Jinushi, M., Takehara, T., Kanto, T., Tatsumi, T., Groh, V., Spies, T., Miyagi, T., Suzuki, T., Sasaki, Y., & Hayashi, N. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1249 · Cited by 260
Chiesa, M. D., Vitale, M., Carlomagno, S., Ferlazzo, G., Moretta, L., & Moretta, A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323986 · Cited by 258
Müller, N., Michen, S., Tietze, S., Töpfer, K., Schulte, A., Lamszus, K., Schmitz, M., Schackert, G., Pastan, I., & Temme, A. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000082 · Cited by 253
James, S. E., Greenberg, P. D., Jensen, M. C., Lin, Y., Wang, J., Till, B. G., Raubitschek, A. A., Forman, S. J., & Press, O. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.7028 · Cited by 249
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Cartellieri, M., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Ehninger, A., von Bonin, M., Bejestani, E. P., Ehninger, G., & Bachmann, M. P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.61 · Cited by 247
Advantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
Self-citationChen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 242
Reiners, K. S., Topolar, D., Henke, A., Simhadri, V. R., Kessler, J., Sauer, M., Bessler, M., Hansen, H. P., Tawadros, S., Herling, M., et al. (2013) · Blood · doi:10.1182/blood-2013-01-476606 · Cited by 239
Shah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12810 · Cited by 220
Self-citationSchlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose-John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E. P., Textor, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3017 · Cited by 216
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Self-citationFerlazzo, G., Morandi, B., D'Agostino, A., Meazza, R., Melioli, G., Moretta, A., & Moretta, L. (2003) · European Journal of Immunology · doi:10.1002/immu.200310004 · Cited by 206
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
Tam, Y. K., Maki, G., Miyagawa, B., Hennemann, B., Tonn, T., & Klingemann, H.-G. (1999) · Human Gene Therapy · doi:10.1089/10430349950018030 · Cited by 203
Self-citationNatural killer cell‐based immunotherapy in cancer: current insights and future prospects
Sutlu, T., & Alici, E. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02121.x · Cited by 200
Draghi, M., Pashine, A., Sanjanwala, B., Gendzekhadze, K., Cantoni, C., Cosman, D., Moretta, A., Valiante, N. M., & Parham, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2688 · Cited by 200
Baginska, J., Viry, E., Paggetti, J., Medves, S., Berchem, G., Moussay, E., & Janji, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00490 · Cited by 198
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors
Alkins, R., Burgess, A., Ganguly, M., Francia, G., Kerbel, R., Wels, W. S., & Hynynen, K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2609 · Cited by 197
Self-citationBoissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Self-citationEsser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Self-citationOelsner, S., Friede, M. E., Zhang, C., Wagner, J., Badura, S., Bader, P., Ullrich, E., Ottmann, O. G., Klingemann, H., Tonn, T., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.10.009 · Cited by 188
Self-citationGenßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., Steinbach, J. P., & Wels, W. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 187
Self-citationSahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Self-citationBruno, A., Ferlazzo, G., Albini, A., & Noonan, D. M. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju200 · Cited by 184
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Lin, K.-W., Jares, A., Firor, A. E., Shuai, X., Salman, H., Golightly, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.8 · Cited by 184
Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Yok Tsang, K., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
Binyamin, L., Alpaugh, R. K., Hughes, T. L., Lutz, C. T., Campbell, K. S., & Weiner, L. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6392 · Cited by 176
Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M., & Cairo, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 174
Pachynski, R. K., Zabel, B. A., Kohrt, H. E. K., Tejeda, N., Monnier, J., Swanson, C., Holzer, A. K., Gentles, A. J., Sperinde, G. V., Edalati, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112124 · Cited by 168
Antileukemia activity of a natural killer cell line against human leukemias.
Yan, Y., Steinherz, P. G., Klingemann, H., Dennig, D., Childs, B. H., McGuirk, J. P., & O’Reilly, R. J. (1998) · PubMed · Cited by 167
Daldrup-Link, H. E., Meier, R., Rudelius, M., Piontek, G., Piert, M., Metz, S., Settles, M., Uherek, C., Wels, W., Schlegel, J., et al. (2005) · European Radiology · doi:10.1007/s00330-004-2526-7 · Cited by 167
Self-citationBoissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Self-citationRole of non-classical MHC class I molecules in cancer immunosuppression
Kochan, G., Escors, D., Breckpot, K., & Guerrero-Setas, D. (2013) · OncoImmunology · doi:10.4161/onci.26491 · Cited by 159
Schnurr, M. M., Scholz, C., Rothenfußer, S., Galambos, P., Dauer, M., Röbe, J., Endres, S., & Eigler, A. (2002) · PubMed · Cited by 147
Favier, B., LeMaoult, J., Lesport, E., & Carosella, E. D. (2009) · The FASEB Journal · doi:10.1096/fj.09-135194 · Cited by 146
Koehl, U., Brehm, C., Huenecke, S., Zimmermann, S. Y., Kloeß, S., Bremm, M., Ullrich, E., Soerensen, J., Quaiser, A., Erben, S., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00118 · Cited by 143
Self-citationEckl, J., Büchner, A., Prinz, P. U., Riesenberg, R., Siegert, S. I., Kammerer, R., Nelson, P. J., & Noeßner, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0806-7 · Cited by 142
Boissel, L., Betancur, M., Lu, W., Wels, W. S., Marino, T., Etten, R. A. V., & Klingemann, H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.634048 · Cited by 138
Self-citationVelardi, A., Ruggeri, L., Mancusi, A., Aversa, F., & Christiansen, F. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.07.015 · Cited by 137
Alkins, R. D., Burgess, A., Kerbel, R. S., Wels, W. S., & Hynynen, K. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov318 · Cited by 135
Self-citationLanier, L. L., Yu, G., & Phillips, J. H. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.5.1571 · Cited by 134
Tam, Y. K., Miyagawa, B., HO, V. C., & Klingemann, H.-G. (1999) · Journal of Hematotherapy · doi:10.1089/106161299320316 · Cited by 133
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Chen, K. H., Wada, M., Firor, A. E., Pinz, K. G., Jares, A., Liu, H., Salman, H., Golightly, M. G., Lan, F., Jiang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11019 · Cited by 118
Jacoby, E., Yang, Y., Qin, H., Chien, C. D., Kochenderfer, J. N., & Fry, T. J. (2015) · Blood · doi:10.1182/blood-2015-08-664250 · Cited by 115
Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes
Waldmann, T. A., Dubois, S. P., & Tagaya, Y. (2001) · Immunity · doi:10.1016/s1074-7613(01)00093-0 · Cited by 115
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer
Davis, Z., Felices, M., Verneris, M. R., & Miller, J. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000156 · Cited by 114
Nagashima, S., Mailliard, R. B., Kashii, Y., et al. (1998) · Blood · doi:10.1182/blood.v91.10.3850 · Cited by 113
Bringing natural killer cells to the clinic: ex vivo manipulation
Childs, R. W., & Berg, M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.234 · Cited by 110
Hombach, A. A., Schildgen, V., Heuser, C., Finnern, R., Gilham, D. E., & Abken, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4650 · Cited by 106
Challenges of cancer therapy with natural killer cells
Klingemann, H. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.09.007 · Cited by 103
Elboim, M., Gazit, R., Gur, C., Ghadially, H., Betser-Cohen, G., & Mandelboim, O. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901644 · Cited by 100
Biology and clinical application of CAR T cells for B cell malignancies
Davila, M. L., & Sadelain, M. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2039-6 · Cited by 91
Expanded and armed natural killer cells for cancer treatment
Shimasaki, N., Coustan‐Smith, E., Kamiya, T., & Campana, D. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.013 · Cited by 90
Zhao, Q., Ahmed, M., Tassev, D. V., Hasan, A., Kuo, T.-Y., Guo, H.-F., O’reilly, R. J., & Cheung, N. K. (2015) · Leukemia · doi:10.1038/leu.2015.125 · Cited by 85
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
Tassev, D. V., Cheng, M., & Cheung, N. K. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.66 · Cited by 72
What is natural in natural killer cells?
Vivier, É. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.07.004 · Cited by 72
Zhang, J., Sun, R., Wei, H., Zhang, J., & Tian, Z. (2004) · PubMed · Cited by 71
Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
Zhang, G., Liu, R., Zhu, X., Wang, L., Ma, J., Han, H., Wang, X., Zhang, G., He, W. Z., Wang, W., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.45 · Cited by 70
Fauriat, C., Moretta, A., Olive, D., & Costello, R. T. (2005) · Blood · doi:10.1182/blood-2005-03-1270 · Cited by 69
Liu, H., Yang, B. Y., Sun, T., Lin, L., Hu, Y., Deng, M., Yang, J., Liu, T., Li, J., Sun, S., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3548 · Cited by 68
Optical Imaging of Cellular Immunotherapy against Prostate Cancer
Tavri, S., Jha, P., Meier, R., et al. (2009) · Molecular Imaging · doi:10.2310/7290.2009.00002 · Cited by 67
Natural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies
van Elssen, C. H. M. J., Oth, T., Germeraad, W. T. V., Bos, G. M. J., & Vanderlocht, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2302 · Cited by 54
Klöß, S., Chambron, N., Gardlowski, T., Arseniev, L., Koch, J., Esser, R., Glienke, W., Seitz, O., & Koehl, U. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1055993 · Cited by 51
Seidel, D., Shibina, A., Siebert, N., Wels, W. S., Reynolds, C. P., Huebener, N., & Lode, H. N. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1669-5 · Cited by 48
Self-citationTargeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
Konstantinidis, K. V., Alici, E., Aints, A., Christensson, B., Ljunggren, H., & Dilber, M. S. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.003 · Cited by 47
Gerstmayer, B., Altenschmidt, U., Hoffmann, M., & Wels, W. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.4584 · Cited by 46
Self-citationSignaling function of reconstituted CD16: ζ: γ receptor complex isoforms
Vivier, É., Rochet, N., Ackerly, M., Petrlni, J., Levine, H., Daley, J., & Anderson, P. (1992) · International Immunology · doi:10.1093/intimm/4.11.1313 · Cited by 46
Meier, R., Golovko, D. M., Tavri, S., Henning, T. D., Knopp, C., Piontek, G., Rudelius, M., Heinrich, P., Wels, W. S., & Daldrup-Link, H. E. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22652 · Cited by 45
Self-citationKiller Cell Ig-Like Receptor-Dependent Signaling by Ig-Like Transcript 2 (ILT2/CD85j/LILRB1/LIR-1)
Kirwan, S. E., & Burshtyn, D. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5006 · Cited by 34
Oberoi, P., Jabulowsky, R. A., Bähr-Mahmud, H., & Wels, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061267 · Cited by 32
Self-citationZhang, J., Sun, R., Wei, H., et al. (2004) · Oncology Reports · doi:10.3892/or.11.5.1097 · Cited by 27
Clemenceau, B., Valsesia‐Wittmann, S., Jallas, A.-C., Vivien, R., Rousseau, R. F., Marabelle, A., Caux, C., & Vié, H. (2015) · Journal of Immunology Research · doi:10.1155/2015/482089 · Cited by 27
Wai, L., Garcia, J. A., Martinez, O. M., & Krams, S. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002597 · Cited by 25
Arming NK cells with enhanced antitumor activity: CARs and beyond
Oberoi, P., & Wels, W. S. (2013) · OncoImmunology · doi:10.4161/onci.25220 · Cited by 25
Self-citation
Cited by
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Metadata
- Authors
- Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-05-18
- Volume
- 8
- Pages
- 533-533
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2615682320
- Cited by
- 306
- References
- 139
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.